Abstract | BACKGROUND: METHODS: In a multicentre, randomised, placebo-controlled trial, 1959 patients with a proven acute myocardial infarction and a left-ventricular ejection fraction of </=40% were randomly assigned 6.25 mg carvedilol (n=975) or placebo (n=984). Study medication was progressively increased to a maximum of 25 mg twice daily during the next 4-6 weeks, and patients were followed up until the requisite number of primary endpoints had occurred. The primary endpoint was all-cause mortality or hospital admission for cardiovascular problems. Analysis was by intention to treat. FINDINGS: Although there was no difference between the carvedilol and placebo groups in the number of patients with the primary endpoint (340 [35%] vs 367 [37%], hazard ratio 0.92 [95% CI 0.80-1.07]), all-cause mortality alone was lower in the carvedilol group than in the placebo group (116 [12%] vs 151 [15%], 0.77 [0.60-0.98], p=0.03). Cardiovascular mortality, non-fatal myocardial infarctions, and all-cause mortality or non-fatal myocardial infarction were also lower on carvedilol than on placebo. INTERPRETATION:
|
Authors | H J Dargie |
Journal | Lancet (London, England)
(Lancet)
Vol. 357
Issue 9266
Pg. 1385-90
(May 05 2001)
ISSN: 0140-6736 [Print] England |
PMID | 11356434
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic beta-Antagonists
- Carbazoles
- Propanolamines
- Carvedilol
|
Topics |
- Adrenergic beta-Antagonists
(administration & dosage, therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Carbazoles
(administration & dosage, therapeutic use)
- Carvedilol
- Drug Administration Schedule
- Endpoint Determination
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(complications, drug therapy, mortality)
- Propanolamines
(administration & dosage, therapeutic use)
- Treatment Outcome
- Ventricular Dysfunction, Left
(complications)
|